HEMOPHILIA.ORG > BLEEDING DISORDERS INFO
TYPES > HEMOPHILIA A
(Factor VIII Deficiency)
What Is It?
Hemophilia is a bleeding disorder caused by a deficiency in one of the blood
clotting factors. Hemophilia A (often called classic hemophilia) accounts
for about 80% of all hemophilia cases. It is a deficiency in clotting factor
Hemophilia A is a hereditary disorder in which the clotting ability of the
blood is impaired and excessive bleeding results. Small wounds and punctures
are usually not a problem, but uncontrolled internal bleeding can result
in pain and swelling and permanent damage, especially to joints and muscles.
Severity of symptoms can vary and severe forms become apparent early on.
Prolonged bleeding is the hallmark of hemophilia A and typically occurs
when an infant is circumcised. Additional bleeding manifestations make their
appearance when the infant becomes mobile. Mild cases may go unnoticed until
later in life when there is excessive bleeding and clotting problems in
response to surgery or trauma. Internal bleeding may happen anywhere, and
bleeding into joints is common.
The incidence of hemophilia A is one in 10,000 live male births. About 17,000
Americans have hemophilia. Women may have it, but it's very rare. With treatment
and management, the outcome is good. Most men with hemophilia are able to
lead relatively normal lives.
Hemophilia A is caused by an inherited sex-linked recessive trait with the
defective gene located on the X chromosome. Females are carriers of this
trait. Fifty percent of the male offspring of female carriers have the disease,
and 50% of their female offspring are carriers. All female children of a
male with hemophilia are carriers of the trait.
One third of all cases of hemophilia A occur when there is no family history
of the disorder. In these cases, hemophilia develops as the result of a
new or spontaneous gene mutation.
Genetic counseling may be advised for carriers. Female carriers can be identified
A woman is definitely a hemophilia carrier if she
the biological daughter of a man with hemophilia;
the biological mother of more than one son with hemophilia;
the biological mother of one hemophilic son who has at least one
other blood relative with hemophilia.
A woman may or may not be a hemophilia carrier if
the biological mother of one son with hemophilia;
the sister of a male with hemophilia;
an aunt, cousin or niece of an affected male related through maternal
the biological grandmother of one grandson with hemophilia.
The only way a woman could ever have hemophilia is if her father has it
and her mother carries the gene. Women who are carriers can also be symptomatic
carriers, whereby they do experience factor deficiencies.
Symptoms & Diagnosis
Hemophilia is caused by several different gene abnormalities. The severity
of the symptoms of hemophilia A depends on how a particular gene abnormality
affects the activity of factor VIII. When the activity is less than 1 percent
of normal, episodes of severe bleeding occur and recur for no apparent reason.
Bleeding into joints and associated pain and swelling
Gastrointestinal tract and urinary tract hemorrhage
Blood in the urine or stool
Prolonged bleeding from cuts, tooth extraction, and surgery
People whose clotting activity is 5 percent of normal may have only mild
hemophilia. They rarely have unprovoked bleeding episodes, but surgery or
injury may cause uncontrolled bleeding, which can be fatal. Milder hemophilia
may not be diagnosed at all, although some people whose clotting activity
is 10 to 25 percent of normal may have prolonged bleeding after surgery,
dental extractions, or a major injury.
Generally, the first bleeding episode occurs before 18 months of age, often
after a minor injury. A child who has hemophilia bruises easily. Even an
injection into a muscle can cause bleeding that results in a large bruise
(hematoma). Recurring bleeding into the joints and muscles can ultimately
lead to crippling deformities. Bleeding can swell the base of the tongue
until it blocks the airway, making breathing difficult. A slight bump on
the head can trigger substantial bleeding in the skull, causing brain damage
A doctor may suspect hemophilia in a child whose bleeding is unusual. A
laboratory analysis of blood samples can determine whether the child's clotting
is abnormally slow. If it is, the doctor can confirm the diagnosis of hemophilia
A and can determine the severity by testing the activity of factor VIII.
Hemophilia is treated by infusing the missing clotting factor. The amount
infused depends upon the severity of bleeding, the site of the bleeding,
and the size of the patient. In the past, mild hemophilia A was typically
treated with infusion of cryoprecipitate or desmopressin acetate (DDAVP),
which causes release of factor VIII that is stored within the body on the
lining of blood vessels. Today, experts recommend desmopressin injection
or Stimate nasal spray.
Clotting factors are found in plasma and, to a greater extent, in plasma
concentrates. Some plasma concentrates are intended for home use and can
be self-administered, either on a regular basis to prevent bleeding or at
the first sign of bleeding. More often, they are administered three times
a day, but both the dose and frequency depend on the severity of the bleeding
problem. The dose is adjusted according to the results of periodic blood
tests. During a bleeding episode, more clotting factors are needed.
To prevent a bleeding crisis, people with hemophilia and their families
can be taught to administer factor VIII concentrates at home at the first
signs of bleeding. People with severe forms of the disease may need regular
prophylactic infusions, which bring factor levels higher than 1% to prevent
Depending on the severity of the disease, DDAVP or factor VIII concentrate
may be given prior to dental extractions and surgery to prevent bleeding.
Immunization with hepatitis B vaccine is necessary because of the increased
risk of exposure to hepatitis due to frequent infusions of blood products.
Gene therapy and fetal tissue implant techniques are under study as possible
People who have hemophilia should avoid situations that might cause bleeding.
They should be conscientious about dental care so they won't need to have
teeth extracted. People who have hemophilia should also avoid certain drugs
that can aggravate bleeding problems:
Certain analgesics such as nonsteroidal anti-inflammatory drugs
Treatment should be coordinated by a healthcare practitioner who is expert
in the field, such as a hematologist of hemophilia treatment center nurse.
The National Hemophilia Foundation's Medical and Scientific Advisory Council
(MASAC) made recommendations for treatment of hemophilia in November of
1999. They include:
Factor VIII products for patients who are HIV seronegative, including
Recombinant factor VIII, especially for young and newly diagnosed patients
who have not received any blood or plasma-derived products.
Immunoaffinity purified factor VIII concentrates for patients who
are HIV seropositive.
Cryoprecipitate is not recommended because of the risk of HIV and
hepatitis infection. Despite greatly improved screening and purification
for viral inactivation in blood products, cryoprecipitate can still contain
Mild hemophilia A should be treated with desmopressin, in a DDAVP
injection or Stimate nasal spray.
Chronic joint deformities, caused by recurrent bleeding into the
joint, may be managed by an orthopedic specialist.
Intracerebral hemorrhage is another possible complication.
Some persons with hemophilia develop antibodies to transfused factor VIII.
As a result, the transfusions are ineffective. If antibodies are detected
in blood samples, the dosage of the plasma concentrates may be increased,
or different types of clotting factors or drugs to reduce the antibody levels
may be used.
In the past, the plasma concentrates carried the risk of transmitting blood-borne
diseases such as hepatitis and AIDS. About 60 percent of persons with hemophilia
who were treated with plasma concentrates in the early 1980s were infected
with HIV. However, the risk of transmitting HIV infection through plasma
concentrates has been virtually eliminated by today's use of screened and
processed blood and a genetically engineered factor VIII (Recombinant).
The information contained on the NHF web site is provided for your general
information only. NHF does not give medical advice or engage in the practice
of medicine. NHF under no circumstances recommends particular treatment
for specific individuals and in all cases recommends that you consult your
physician or local treatment center before pursuing any course of treatment.
All information and content on this web site
are protected by copyright. All rights are reserved. Users are prohibited
from modifying, copying, distributing, transmitting, displaying, publishing,
selling, licensing, creating derivative works, or using any information
available on or through the site for commercial or public purposes.